Pureos Bioventures leads CHF 15.2m round for Araris

Also participating in the round were new investors 4Bio Capital and BtoV Partners, as well as existing investors Redalpine, VI Partners and Schroder Adveq.

The round is an extension of the CHF 2.5m round previously raised by the company in August 2019, which was backed by Redalpine and VI Partners.

Following the round, Dominik Escher, Dmitry Kuzmin, Michael Sidler and Arnd Kaltofen will join the company's board.

Araris plans to use the fresh capital to nominate a clinical candidate and advance its lead programme into pre-clinical and clinical development.

Company
Araris was founded in 2019 as a spinout from the Paul Scherrer Institute and ETH Zurich. The company develops antibody-drug conjugate-linker technology (ADC) and aims to commercialise the treatment.

People
Araris Biotech – Philipp Spycher (co-founder, CEO); Dragan Grabulovski (co-founder, founding chairman).
Pureos Bioventures – Dominik Escher (managing partner).
4Bio Capital – Dmitry Kuzmin (managing partner).
VI Partners – Arnd Kaltofen (partner).
Redalpine  – Michael Sidler (founding partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Healthcare
• Venture
• Switzerland